interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Lifitegrast

Generic competition · all medicines · read 12 November 2026

Is there a generic of Lifitegrast, and who makes it?

Lifitegrast appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 7.1 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Lifitegrast1 dosage-form group in the Orange Book
0generic makers listed
  1. Lifitegrast appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 7.1 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution/Drops, Ophthalmic

Brand listed, no generic listed as marketed

Brand listed as marketed: Xiidra. No generic is listed as marketed (3 generic products listed as discontinued).

2015202020252030203501brand 2016data datePatent 9447077 listed to expire 15 April 2029Patent 8367701 listed to expire 15 April 2029Patent 8168655 listed to expire 9 May 2029Patent 7314938 listed to expire 25 June 2029Patent 9890141 listed to expire 21 October 2030Patent 9353088 listed to expire 21 October 2030Patent 8927574 listed to expire 12 November 2030Patent 9085553 listed to expire 25 July 2033Patent 11058677 listed to expire 18 December 2033
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 15 April 2029Patent 9447077
  • 15 April 2029Patent 8367701 drug product
  • 9 May 2029Patent 8168655
  • 25 June 2029Patent 7314938 drug substance
  • 21 October 2030Patent 9890141 drug substance
  • 21 October 2030Patent 9353088 drug product
  • 12 November 2030Patent 8927574 drug product
  • 25 July 2033Patent 9085553 drug product

1 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.